Your browser doesn't support javascript.
loading
Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.
Gardin, Anne; Shakeri-Nejad, Kasra; Feller, Andrea; Huth, Felix; Neelakantham, Srikanth; Dumitras, Swati.
Afiliação
  • Gardin A; Novartis Institutes for Biomedical Research, Basel, Switzerland. anne.gardin@novartis.com.
  • Shakeri-Nejad K; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Feller A; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Huth F; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Neelakantham S; Novartis Healthcare Pvt. Ltd., Hyderabad, India.
  • Dumitras S; Novartis Institutes for Biomedical Research, Basel, Switzerland.
Eur J Clin Pharmacol ; 75(11): 1565-1574, 2019 Nov.
Article em En | MEDLINE | ID: mdl-31392364

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azetidinas / Compostos de Benzil / Itraconazol / Citocromo P-450 CYP3A / Citocromo P-450 CYP2C9 / Inibidores do Citocromo P-450 CYP3A / Moduladores do Receptor de Esfingosina 1 Fosfato Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azetidinas / Compostos de Benzil / Itraconazol / Citocromo P-450 CYP3A / Citocromo P-450 CYP2C9 / Inibidores do Citocromo P-450 CYP3A / Moduladores do Receptor de Esfingosina 1 Fosfato Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article